BOSTON SCIENTIFIC CORP（BSX）の決算・業績分析
BOSTON SCIENTIFIC CORPの2025年有価証券報告書をAI分析。売上高$20.1B(+19.9%)。営業利益$3.6B。Health Care。
目次
BOSTON SCIENTIFIC CORPの2025年度 業績サマリー
BOSTON SCIENTIFIC CORP（証券コード: BSX）の2025年度決算・業績分析。売上高は$20.1B（前年比+19.9%）。営業利益は$3.6B（前年比+38.8%）。純利益は$2.9B（前年比+56.7%）。有価証券報告書を基に、業績変化の要因・リスク・見通し・セグメント構成を AI が分析しました。
BOSTON SCIENTIFIC CORPの2024年度 注目ポイント
※ 直近の2025年度XBRLデータは取込済みですが、AI分析は2024年度の10-Kを対象としています。
- FY2024 revenue reached $12.7B (+6.7% YoY) with operating income surging to $1.6B (+37.5% YoY) (XBRL).
- Net income declined to $698M (-32.9% YoY) despite strong gross margin of 68.8% (XBRL).
- R&D investment of $1.3B (XBRL) underscores focus on innovation, a key competitive advantage (10-K).
BOSTON SCIENTIFIC CORPの売上高変化の要因
- •FY2024 revenue of $12.7B reflects 5-year CAGR of +7.7% (XBRL). Revenue growth accelerated from FY2023 ($11.9B) to FY2024, though segment-specific data is unavailable (N/A). Operating income surged to $1.6B (+37.5% YoY) (XBRL), driven by cost efficiencies and product innovation.
BOSTON SCIENTIFIC CORPの営業利益変化の要因
- •Gross margin of 68.8% (XBRL) and operating margin of 13.0% (XBRL) highlight efficient cost management. However, net margin fell to 5.5% (-32.9% YoY) (XBRL), likely due to higher R&D expenses ($1.3B XBRL) and one-time charges. Operating income growth (+37.5% YoY) outpaced revenue growth, indicating improved operational leverage.
BOSTON SCIENTIFIC CORPの事業リスクと対応
Intense competition and rapid technological changes may render products obsolete (10-K).
Market size declines, pricing pressures, and reduced procedure volumes could harm financial performance (10-K).
Healthcare consolidation may force price concessions or limit market access (10-K).
Regulatory and reimbursement challenges could impact product approvals and sales (10-K).
Emerging competitors and digital technologies (e.g., AI) may disrupt market position (10-K).
BOSTON SCIENTIFIC CORPの事業内容
Boston Scientific Corp (BSX) is a global developer, manufacturer, and marketer of medical devices for interventional specialties, generating revenue through sales of innovative, less-invasive solutions (10-K). Key segments include MedSurg (endoscopy, urology) with products like Resolution 360™ Clips and SpyGlass™ systems, and Cardiovascular (details unspecified) (10-K). Competitive advantages include R&D investment ($1.3B FY2024 XBRL), digital tools, and strategic acquisitions (10-K).
BOSTON SCIENTIFIC CORPのAI業績分析レポート（2024年度）
Boston Scientific Corp (BSX) FY2024 Annual Report Analysis
Highlights
Business Overview
Boston Scientific Corp (BSX) is a global developer, manufacturer, and marketer of medical devices for interventional specialties, generating revenue through sales of innovative, less-invasive solutions (10-K). Key segments include MedSurg (endoscopy, urology) with products like Resolution 360™ Clips and SpyGlass™ systems, and Cardiovascular (details unspecified) (10-K). Competitive advantages include R&D investment ($1.3B FY2024 XBRL), digital tools, and strategic acquisitions (10-K).
Revenue Analysis
FY2024 revenue of $12.7B reflects 5-year CAGR of +7.7% (XBRL). Revenue growth accelerated from FY2023 ($11.9B) to FY2024, though segment-specific data is unavailable (N/A). Operating income surged to $1.6B (+37.5% YoY) (XBRL), driven by cost efficiencies and product innovation.
Profitability Analysis
Gross margin of 68.8% (XBRL) and operating margin of 13.0% (XBRL) highlight efficient cost management. However, net margin fell to 5.5% (-32.9% YoY) (XBRL), likely due to higher R&D expenses ($1.3B XBRL) and one-time charges. Operating income growth (+37.5% YoY) outpaced revenue growth, indicating improved operational leverage.
Balance Sheet Analysis
Equity ratio of 50.0% (XBRL) and current ratio of 1.32x (XBRL) suggest moderate leverage and liquidity. Cash reserves of $928M (XBRL) provide financial flexibility. Total assets grew to $35.1B (XBRL) in FY2024, with total equity at $17.6B (XBRL).
Cash Flow Analysis
Operating cash flow of $1.5B (XBRL) supported free cash flow (FCF) of $938M (XBRL), calculated as OCF minus CapEx ($588M XBRL). Dividends paid totaled $55M (XBRL), with no buybacks mentioned (N/A).
Working Capital Analysis
N/A
Risks
Outlook
N/A
Historical Time Series
| Metric | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | 9.8B | 10.7B | 9.9B | 11.9B | 12.7B | 14.2B |
| Operating Income | 1.5B | 1.5B | -80M | 1.2B | 1.6B | 2.3B |
| Net Income | 1.7B | 4.7B | -82M | 1.0B | 698M | 1.6B |
| Total Assets | 30.6B | 30.8B | 32.2B | 32.5B | 35.1B | 39.4B |
| Total Equity | 13.9B | 13.9B | 15.3B | 16.6B | 17.6B | 21.8B |
| Operating Cash Flow | 310M | 1.8B | 1.5B | 1.9B | 1.5B | 2.5B |
Health Careの企業一覧
BOSTON SCIENTIFIC CORPと同じ「Health Care」セクターの企業